PhilaTRANQia: A Primer on Philadelphia's Rising Xylazine Epidemic

Document Type

Presentation

Loading...

Media is loading
 

Publication Date

1-25-2024

Comments

Presentation: 26:41

Abstract

Xylazine

- Developed in 1962 by Farbenfabriken Bayer as antihypertensive in humans

  • Abandoned due to severe sedative effects
  • 1972 FDA approves for veterinary use as tranquilizer

- Stimulates α2-adrenergic receptors

- Analog of clonidine

- Concentrates in kidney and CNS

- Sedative, muscle relaxant, and analgesic properties

Language

English

This document is currently not available here.

Share

COinS